These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 27375785)

  • 1. Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy.
    Jo SD; Ku SH; Won YY; Kim SH; Kwon IC
    Theranostics; 2016; 6(9):1362-77. PubMed ID: 27375785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine?
    Blau R; Krivitsky A; Epshtein Y; Satchi-Fainaro R
    Drug Resist Updat; 2016 Jul; 27():39-58. PubMed ID: 27449597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-Targeted Nanotheranostics: Recent Advances and Perspectives.
    Ma Y; Huang J; Song S; Chen H; Zhang Z
    Small; 2016 Sep; 12(36):4936-4954. PubMed ID: 27150247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supramolecular cancer nanotheranostics.
    Zhou J; Rao L; Yu G; Cook TR; Chen X; Huang F
    Chem Soc Rev; 2021 Feb; 50(4):2839-2891. PubMed ID: 33524093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Versatile Nanosystem-Based Cancer Theranostics: Design Inspiration and Predetermined Routing.
    Opoku-Damoah Y; Wang R; Zhou J; Ding Y
    Theranostics; 2016; 6(7):986-1003. PubMed ID: 27217832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy.
    Zhu L; Zhou Z; Mao H; Yang L
    Nanomedicine (Lond); 2017 Jan; 12(1):73-87. PubMed ID: 27876448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2D Nanomaterials for Cancer Theranostic Applications.
    Cheng L; Wang X; Gong F; Liu T; Liu Z
    Adv Mater; 2020 Apr; 32(13):e1902333. PubMed ID: 31353752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease-activated nanomaterials for targeted cancer theranostics.
    Chan YC; Hsiao M
    Nanomedicine (Lond); 2017 Sep; 12(18):2153-2159. PubMed ID: 28814163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theranostic barcoded nanoparticles for personalized cancer medicine.
    Yaari Z; da Silva D; Zinger A; Goldman E; Kajal A; Tshuva R; Barak E; Dahan N; Hershkovitz D; Goldfeder M; Roitman JS; Schroeder A
    Nat Commun; 2016 Nov; 7():13325. PubMed ID: 27830705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theranostic Advances in Breast Cancer in Nuclear Medicine.
    Vahidfar N; Aghanejad A; Ahmadzadehfar H; Farzanehfar S; Eppard E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sonodynamic therapy (SDT): a novel strategy for cancer nanotheranostics.
    Pan X; Wang H; Wang S; Sun X; Wang L; Wang W; Shen H; Liu H
    Sci China Life Sci; 2018 Apr; 61(4):415-426. PubMed ID: 29666990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Special Issue "Recent Advances in Precision Nanomedicine for Cancer".
    Brignole C; Pastorino F
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32927825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Trends and Developments in Multifunctional Nanoparticles for Cancer Theranostics.
    Rabaan AA; Bukhamsin R; AlSaihati H; Alshamrani SA; AlSihati J; Al-Afghani HM; Alsubki RA; Abuzaid AA; Al-Abdulhadi S; Aldawood Y; Alsaleh AA; Alhashem YN; Almatouq JA; Emran TB; Al-Ahmed SH; Nainu F; Mohapatra RK
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theranostics based on AIEgens.
    Wang D; Lee MMS; Xu W; Kwok RTK; Lam JWY; Tang BZ
    Theranostics; 2018; 8(18):4925-4956. PubMed ID: 30429878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted nanotheranostics for personalized cancer therapy.
    Diou O; Tsapis N; Fattal E
    Expert Opin Drug Deliv; 2012 Dec; 9(12):1475-87. PubMed ID: 23092183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A PEGylation-Free Biomimetic Porphyrin Nanoplatform for Personalized Cancer Theranostics.
    Cui L; Lin Q; Jin CS; Jiang W; Huang H; Ding L; Muhanna N; Irish JC; Wang F; Chen J; Zheng G
    ACS Nano; 2015; 9(4):4484-95. PubMed ID: 25830219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theranostics - a sure cure for cancer after 100 years?
    Song Y; Zou J; Castellanos EA; Matsuura N; Ronald JA; Shuhendler A; Weber WA; Gilad AA; Müller C; Witney TH; Chen X
    Theranostics; 2024; 14(6):2464-2488. PubMed ID: 38646648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cancer precision theranostics: a focus on multifunctional gold nanoparticles.
    Cabral RM; Baptista PV
    Expert Rev Mol Diagn; 2014 Nov; 14(8):1041-52. PubMed ID: 25314939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide-modulated self-assembly as a versatile strategy for tumor supramolecular nanotheranostics.
    Li S; Zou Q; Xing R; Govindaraju T; Fakhrullin R; Yan X
    Theranostics; 2019; 9(11):3249-3261. PubMed ID: 31244952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
    Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.